# Animal Model For Testing Market

> Animal Model for Testing Market Research Report By Animal Type (Rodents (Mice and Rats), Non-Rodents (Rabbits, Dogs, and Primates)), By Application (Drug Discovery and Development, Toxicity Testing, Safety Assessment, Disease Modeling), By Technology (Genetically Modified Animal Models, Non-Genetically Modified Animal Models, Patient-Derived Xenograft (PDX) Models), By End-User (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), Academic Research Institutions), By Modality (In Vivo, In Vitro, Ex Vivo) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035.

- **Forecast Period:** 2025 - 2035
- **CAGR:** 10.09%
- **2024:** $ 2.09 Billion
- **2025:** $ 2.3 Billion
- **2035:** $ 6.02 Billion
- **Key Players:** Charles River Laboratories (US), Envigo (US), Taconic Biosciences (US), Harlan Laboratories (US), Crown Bioscience (US), Laboratory Corporation of America (US), Wuxi AppTec (CN), Inotiv(US)

**Report ID:** MRFR/HC/39411-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** July 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/animal-model-for-testing-market-29720

---

## Market Summary

## **Animal Model for Testing Market Overview**

As per MRFR analysis, the Animal Model for Testing Market Size was estimated at 1.91 (USD Billion) in 2023. The Animal Model for Testing Market Industry is expected to grow from 2.09 (USD Billion) in 2024 to 4.51 (USD Billion) by 2032. The Animal Model for Testing Market CAGR (growth rate) is expected to be around 10.09% during the forecast period (2024 - 2032).

**Key Animal Model for Testing Market Trends Highlighted**

Rapid technological advancements and the growing need for personalized medicine are driving the growth of the  Animal Model for Testing market. The use of animal models in preclinical research remains crucial for understanding disease mechanisms and evaluating the safety and efficacy of new therapies.

Animal models provide researchers with a living system to investigate complex biological processes and test hypotheses that cannot be studied in vitro. The development of genetically modified animals, such as humanized mice, has further enhanced the accuracy and relevance of animal models for human diseases.

Additionally, the increasing focus on personalized medicine has created a demand for patient-derived xenografts, which allow for the study of patient-specific tumors in an animal model. These trends are expected to continue to drive the growth of the Animal Model for Testing market in the coming years.

Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review
**Animal Model for Testing Market Drivers**
**Increasing Prevalence of Chronic Diseases**

The rising incidence of chronic diseases, such as cancer, cardiovascular diseases, and neurodegenerative disorders, has fueled the demand for animal models for testing. Animal models are essential for studying the mechanisms of disease development, evaluating the efficacy and safety of new therapies, and developing personalized medicine approaches.

The increasing prevalence of chronic diseases is expected to continue driving the growth of the  Animal Model for Testing market. Growing focus on precision medicine and personalized therapies Technological advancements in animal modeling, such as genetically engineered models and patient-derived xenografts Increasing use of animal models in preclinical safety and efficacy testing of novel therapeutics.

**Technological Advancements**

Technological advancements have revolutionized the field of animal modeling. Genetically engineered animal models, such as knockout and transgenic mice, have enabled researchers to study the effects of specific genes on disease development. Patient-derived xenografts (PDXs) have emerged as a powerful tool for personalized medicine, allowing researchers to study the effects of therapies on tumors that are derived from individual patients.

These technological advancements have significantly enhanced the accuracy and predictive power of animal models, making them more valuable for drug discovery and development.

Development of humanized mouse models for studying human diseases Advances in imaging techniques, such as MRI and PET, for monitoring disease progression in animal models Integration of computational modeling and machine learning to improve the analysis and interpretation of animal data.

**Rising Demand for Non-animal Models**

Growing ethical concerns about animal testing and the need for more cost-effective and efficient models have led to the development of non-animal models. These models include cell-based assays, organ-on-a-chip systems, and computational models. While non-animal models cannot fully replace animal models, they can provide valuable complementary information and help reduce the number of animals used in research.

Increasing investment in the development and validation of non-animal models Growing adoption of non-animal models by regulatory agencies Collaboration between academia, industry, and non-profit organizations to advance the development and use of non-animal models.

**Animal Model for Testing Market Segment Insights**
**Animal Model for Testing Market Animal Type Insights**

The Animal Model for Testing Market is segmented into various animal types, including rodents (mice and rats) and non-rodents (rabbits, dogs, and primates). Each animal type offers unique advantages and disadvantages for specific research applications, leading to variations in market share and growth prospects.

Rodents, particularly mice and rats, are the most commonly used animal models in biomedical research, accounting for a significant portion of the  Animal Model for Testing Market revenue. Their small size, short lifespan, and ease of genetic manipulation make them suitable for a wide range of studies, including toxicology, pharmacology, and disease modeling.

The market for rodents in animal testing is projected to reach USD 10.2 billion by 2026, exhibiting a steady growth rate due to the increasing demand for preclinical safety and efficacy testing of drugs and medical devices.

Non-rodents, such as rabbits, dogs, and primates, are also utilized in animal testing, albeit to a lesser extent compared to rodents. Rabbits are often used in dermal and ocular toxicity studies, while dogs are preferred for cardiovascular and respiratory research. Primates, such as monkeys and apes, are employed in studies requiring higher cognitive functions and complex behavioral assessments.

The market for non-rodents in animal testing is expected to expand at a moderate pace in the coming years, driven by advancements in veterinary medicine and the growing adoption of non-animal testing methods.

The choice of an Animal Model for Testing depends on several factors, including the research question, species-specific biology, ethical considerations, and regulatory requirements. Rodents offer cost-effectiveness, genetic homogeneity, and a well-established body of knowledge, making them the preferred choice for many research applications.

However, for studies involving complex physiological systems or human-specific diseases, non-rodents may be more suitable. Overall, the  Animal Model for Testing Market is highly dynamic and evolving, with continuous advancements in animal welfare, ethical considerations, and alternative testing methods.

The market is expected to witness steady growth in the coming years, driven by the increasing demand for preclinical safety and efficacy testing, as well as the development of more sophisticated and human-relevant animal models.

Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review
**Animal Model for Testing Market Application Insights**

The Application segment of the  Animal Model for Testing Market is categorized into Drug Discovery and Development, Toxicity Testing, Safety Assessment, and Disease Modeling. Drug Discovery and Development is the largest segment and is expected to dominate the market throughout the forecast period.

This growth can be attributed to the increasing demand for animal models in the early stages of drug development to assess the efficacy and safety of new drugs. The Toxicity Testing segment is expected to grow at a significant CAGR due to the growing need for safety assessments of chemicals and consumer products.

The Safety Assessment segment is also expected to grow at a healthy rate due to the increasing regulatory requirements for product safety evaluations. The Disease Modeling segment is expected to witness moderate growth due to the growing use of animal models in understanding disease mechanisms and developing new therapies.

**Animal Model for Testing Market Technology Insights**

The Technology segment of the  Animal Model for Testing Market is categorized into Genetically Modified Animal Models, Non-Genetically Modified Animal Models, and Patient-Derived Xenograft (PDX) Models. Genetically Modified Animal Models held the largest market share in 2023, owing to their ability to mimic human diseases more accurately.

Non-Genetically Modified Animal Models are expected to witness significant growth due to their lower cost and ease of use. Patient-derived xenograft (PDX) Models are gaining popularity as they provide a more personalized approach to drug testing.

The Animal Model for Testing Market for Genetically Modified Animal Models is projected to reach USD 6.53 Billion by 2032, exhibiting a CAGR of 4.5%. Non-Genetically Modified Animal Models market is anticipated to grow at a CAGR of 3.1%, reaching USD 5.81 Billion by 2032.

The Patient-Derived Xenograft (PDX) Model market is expected to expand at a CAGR of 4.7%, reaching USD 4.17 Billion by 2032.

**Animal Model for Testing Market End-User Insights**

The Animal Model for Testing Market segmentation by End-User includes Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), and Academic Research Institutions. Pharmaceutical Companies are expected to hold the largest market share due to their extensive use of animal models in drug discovery and development.

Biotechnology Companies are also significant contributors to market growth, driven by their focus on developing innovative therapies. Contract Research Organizations (CROs) play a crucial role in providing animal testing services to pharmaceutical and biotechnology companies, contributing to market expansion.

Academic Research Institutions contribute to the market through their research on animal models for disease mechanisms and therapeutic interventions. The  Animal Model for Testing Market is projected to reach USD 16.42 Billion by 2024, exhibiting a CAGR of 3.6% during the forecast period.

**Animal Model for Testing Market Modality Insights**

The modality segment of the  Animal Model for Testing Market is classified into In Vivo, In Vitro, and Ex Vivo. In 2023, the In Vivo segment held the largest market share due to the extensive use of animal models in preclinical research and drug discovery.

In Vivo models allow researchers to study the effects of drugs and other substances on living animals, providing valuable insights into their safety and efficacy. The In Vitro segment is anticipated to exhibit a significant growth rate during the forecast period owing to the increasing adoption of cell-based assays and organ-on-a-chip technologies.

Ex-vivo models, which involve the study of tissues or organs outside of the body, are also gaining traction due to their ability to provide more controlled and reproducible results.

**Animal Model for Testing Market Regional Insights**

The regional markets for Animal Models for Testing are segmented into North America, Europe, APAC, South America, and MEA. North America held the largest share of the  Animal Model for Testing market in 2023 and is expected to continue to dominate the market over the forecast period.

The growth of the regional market is attributed to the increasing adoption of animal models for drug discovery and safety testing, as well as the presence of major pharmaceutical and biotechnology companies in the region.

The European market for Animal Model for Testing is also expected to grow at a significant rate over the forecast period, driven by the increasing demand for personalized medicine and the growing adoption of animal models for preclinical research.

The APAC market for Animal Models for Testing is expected to witness the highest growth rate over the forecast period due to the rising investments in healthcare infrastructure and the growing demand for animal models for drug discovery and safety testing in the region. South America and MEA are expected to contribute a smaller share to the  Animal Model for Testing market over the forecast period.

Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review
**Animal Model for Testing Market Key Players and Competitive Insights**

Major players in the Animal Model for Testing Market are constantly striving to gain a competitive edge in the industry. These companies are investing heavily in research and development to create innovative products and technologies that cater to the evolving needs of the market.

Leading Animal Model for Testing Market players are focusing on expanding their  footprint through strategic partnerships and acquisitions.

Charles River Laboratories International, Inc. is a leading provider of animal models and related services to the pharmaceutical and biotechnology industries. The company offers a wide range of animal models, including rodents, non-human primates, and dogs.

Charles River also provides a variety of services, such as animal husbandry, veterinary care, and data collection. The company has a  presence with operations in North America, Europe, and Asia.

Envigo RMS, LLC is a leading provider of research models and services to the pharmaceutical and biotechnology industries. The company offers a wide range of animal models, including rodents, rabbits, and dogs. Envigo also provides a variety of services, such as animal husbandry, veterinary care, and data collection. The company has a  presence with operations in North America, Europe, and Asia.

**Key Companies in the Animal Model for Testing Market Include**

**Animal Model for Testing Market Developments**

A recent breakthrough in the market is the development of patient-derived xenograft (PDX) models, which are being increasingly adopted due to their ability to better mimic human tumor growth and response to therapy.

Furthermore, advancements in gene editing technologies, such as CRISPR-Cas9, are enabling the creation of more precise and sophisticated animal models for testing. These advancements are expected to drive market growth in the coming years.

**Animal Model for Testing Market Segmentation Insights**
**Animal Model for Testing Market Animal Type Outlook**

** **
**Animal Model for Testing Market Application Outlook**

** **
**Animal Model for Testing Market Technology Outlook**

** **
**Animal Model for Testing Market End-User Outlook**

**Animal Model for Testing Market Modality Outlook**

**Animal Model for Testing Market Regional Outlook**

## Market Drivers

### Advancements in Genetic Engineering

Advancements in [genetic engineering](https://www.marketresearchfuture.com/reports/genetic-engineering-market-1528) are significantly influencing the Animal Model for Testing Market. The development of genetically modified organisms, particularly in the context of creating disease models, has enhanced the relevance of animal testing. These models allow researchers to study specific diseases and test new therapies with greater precision. The market for genetically engineered animal models is expected to grow substantially, with estimates suggesting a compound annual growth rate of over 10% in the coming years. This growth is indicative of the increasing reliance on sophisticated animal models to facilitate research and development in various therapeutic areas, thereby bolstering the Animal Model for Testing Market.

### Rising Demand for Biopharmaceuticals

The increasing demand for biopharmaceuticals is a pivotal driver for the Animal Model for Testing Market. As the biopharmaceutical sector expands, the need for effective testing methods becomes paramount. Animal models are essential in preclinical testing, providing insights into drug efficacy and safety. In 2025, the biopharmaceutical market is projected to reach approximately 500 billion USD, indicating a robust growth trajectory. This surge necessitates the use of animal models to ensure that new therapies are both safe and effective before they reach human trials. Consequently, the reliance on animal models in the testing phase is likely to intensify, thereby propelling the Animal Model for Testing Market forward.

### Increased Focus on Personalized Medicine

The shift towards personalized medicine is reshaping the landscape of the Animal Model for Testing Market. As healthcare moves towards tailored therapies, the need for specific animal models that can mimic human diseases becomes critical. Personalized medicine requires a deeper understanding of individual responses to treatments, which can be effectively studied using animal models. The market for personalized medicine is projected to reach 2 trillion USD by 2030, highlighting the potential for growth in this area. Consequently, the demand for specialized animal models that can accurately reflect human conditions is likely to increase, driving innovation and expansion within the Animal Model for Testing Market.

### Regulatory Compliance and Safety Standards

Regulatory compliance plays a crucial role in the Animal Model for Testing Market. Regulatory bodies mandate rigorous testing of new drugs and therapies to ensure safety and efficacy. The increasing stringency of regulations surrounding drug approval processes necessitates the use of animal models for preclinical testing. In recent years, the number of regulatory guidelines has expanded, emphasizing the importance of animal testing in the drug development pipeline. This trend suggests that companies are likely to invest more in animal models to meet these compliance requirements, thereby driving growth in the Animal Model for Testing Market. As regulations evolve, the demand for reliable and validated animal models will continue to rise.

### Growing Investment in Research and Development

Growing investment in research and development (R&D) is a significant driver for the Animal Model for Testing Market. As pharmaceutical and biotechnology companies allocate more resources to R&D, the need for effective testing methodologies becomes increasingly apparent. In 2025, R&D spending in the pharmaceutical sector is expected to exceed 200 billion USD, underscoring the commitment to developing new therapies. This investment often translates into a higher demand for animal models, which are integral to the drug development process. The emphasis on innovative therapies and the necessity for thorough testing are likely to propel the Animal Model for Testing Market, as companies seek reliable models to support their research initiatives.

## Future Outlook

The Animal Model for Testing Market is projected to grow at a 10.09% CAGR from 2024 to 2035, driven by advancements in biotechnology, regulatory support, and increasing demand for personalized medicine.

**New opportunities:**

- Development of advanced [in vivo imaging](https://www.marketresearchfuture.com/reports/in-vivo-imaging-market-780) technologies for real-time monitoring.
- Expansion of partnerships with biotech firms for innovative model development.
- Investment in AI-driven data analytics for enhanced predictive modeling capabilities.

By 2035, the market is expected to be robust, reflecting substantial growth and innovation.

## Segment Insights

### By Animal Type: Rodents (Largest) vs. Non-Rodents (Fastest-Growing)

In the Animal Model for Testing Market, rodents, specifically mice and rats, dominate the segment, accounting for the majority of the market share due to their widespread use in preclinical research. Their biological similarities with humans, short life cycles, and ease of handling make them an attractive choice for researchers. Conversely, non-rodents, including rabbits, dogs, and primates, although accounting for a smaller share, are gaining traction as key players in specialized studies relating to complex biological systems.

Rodents (Dominant) vs. Non-Rodents (Emerging)

Rodents, primarily mice and rats, serve as the dominant animal models in testing due to their genetic, biological, and behavioral similarities to humans, facilitating significant advancements in medical research. Their scalability, cost-effectiveness, and high reproductive rates contribute to their widespread acceptance in laboratories. On the other hand, non-rodents, which include rabbits, dogs, and primates, are emerging as vital models for more complex studies, especially for testing human responses and trialing drugs. This segment is favored for its ability to mimic human physiological responses more closely, thus driving innovative research methodologies.

### By Application: Drug Discovery and Development (Largest) vs. Toxicity Testing (Fastest-Growing)

In the Animal Model for Testing Market, the application segments are exhibiting diverse contributions, with Drug Discovery and Development being the largest contributor to market share. This segment encompasses a variety of processes that facilitate the innovation of new therapeutics, making it imperative for the pharmaceutical sciences. Following closely, Toxicity Testing represents the fastest-growing segment, driven by an increasing focus on safety diligence in drug approvals and the rising demand for ethical testing measures.

Drug Discovery and Development (Dominant) vs. Toxicity Testing (Emerging)

The Drug Discovery and Development segment remains the dominant player in the Animal Model for Testing Market due to its critical role in early-stage research and formulation of drugs. This segment involves complex procedures where animal models simulate human disease, leading to groundbreaking discoveries in therapeutics. On the other hand, Toxicity Testing is an emerging segment, propelled by regulatory pressures and societal demands for safe pharmaceuticals. It primarily evaluates the adverse effects of compounds, paving the way for innovations in predictive models that minimize animal use, reflecting a shift towards sustainability in testing methodologies.

### By Technology: Genetically Modified Animal Models (Largest) vs. Patient-Derived Xenograft (PDX) Models (Fastest-Growing)

In the Animal Model for Testing Market, Genetically Modified Animal Models hold the largest market share, being pivotal in genetic research and drug development due to their tailored genetic modifications which enable more accurate testing outcomes. Non-Genetically Modified Animal Models also maintain a significant presence, especially in traditional research sectors, but lag behind PDX models, which are gaining traction due to their ability to better mimic human tumors and offer personalized treatment options. 
Growth trends in this segment are heavily influenced by advancements in genomic technologies and a shift towards more humane and effective testing methods. PDX models are witnessing rapid adoption, making them the fastest-growing segment, driven by increasing demand for personalized medicine and innovative therapeutic approaches. The regulatory push for more relevant and accurate testing models also fuels growth in genetically modified models, as researchers seek to align with modern scientific standards.

Genetically Modified Animal Models (Dominant) vs. Non-Genetically Modified Animal Models (Emerging)

Genetically Modified Animal Models have emerged as the dominant segment in the Animal Model for Testing Market due to their ability to closely replicate human diseases, offering valuable insights and accelerating drug development processes. Their tailored genetic modifications allow researchers to explore specific biological pathways, making them indispensable in oncology and genetic research. Conversely, Non-Genetically Modified Animal Models, while considered an emerging segment, continue to serve vital roles in various applications, particularly where traditional methods are still favored. These models are often more cost-effective and are utilized in preliminary testing phases, although they face pressure from the innovative capabilities provided by genetically modified counterparts. As the landscape of biomedical research evolves, these emerging models are adapting to include more relevant testing parameters.

### By End-User: Pharmaceutical Companies (Largest) vs. Biotechnology Companies (Fastest-Growing)

In the Animal Model for Testing Market, the largest share is held by Pharmaceutical Companies due to their extensive use of animal models in drug development and safety testing. These companies recognize the crucial role that animal testing plays in understanding biological processes and therapeutic effects. Following closely are Biotechnology Companies, which are increasingly leveraging animal models for innovative product development and clinical research, allowing them to effectively translate experimental results into clinical contexts.
The growth trends in this segment are largely driven by the ongoing advancements in biotechnology and personalized medicine. Pharmaceutical Companies continue to allocate substantial resources to research and development, solidifying their market dominance. On the other hand, Biotechnology Companies are experiencing rapid growth as they develop more sophisticated animal models, exploring novel therapies, and addressing rare diseases, which positions them as the fastest-growing segment within the market.

Pharmaceutical Companies (Dominant) vs. Contract Research Organizations (CROs) (Emerging)

Pharmaceutical Companies are the dominant force in the Animal Model for Testing Market, leveraging their established infrastructures and research capabilities to maximize the efficacy of animal models in drug development and regulatory submissions. These companies invest heavily in creating a diverse range of models that cater to various therapeutic areas, ensuring compliance with regulatory standards and maximizing therapeutic success rates. Meanwhile, [Contract Research Organizations](https://www.marketresearchfuture.com/reports/contract-research-organization-market-3322) (CROs) represent an emerging segment, offering specialized services in animal testing for a diverse clientele, including both pharmaceutical and biotechnology firms. CROs are adapting quickly to market needs by providing flexible testing options and proprietary animal models, enabling them to respond swiftly to changing demands in drug research. Their ability to combine expertise in regulatory guidelines with innovative technology positions them as key players in the evolving landscape of animal testing.

### By Modality: In Vivo (Largest) vs. In Vitro (Fastest-Growing)

The 'Animal Model for Testing Market' showcases a diverse segmentation by modality, with 'In Vivo' representing the largest share among the modalities. This segment is predominant due to its extensive application in drug efficacy and safety testing, enabling researchers to obtain robust data from living organisms. Conversely, 'In Vitro' has emerged as a rapidly growing segment, driven by advancements in cell culture technologies and the increasing preference for ethical testing methods that reduce animal usage.

Modality: In Vivo (Dominant) vs. In Vitro (Emerging)

The 'In Vivo' testing modality is recognized as the dominant approach in the animal model market, providing critical insights through biological interactions in live systems, which are essential for understanding the effects of pharmaceuticals. Meanwhile, the 'In Vitro' modality is becoming increasingly popular as an emerging alternative, leveraging advancements in laboratory techniques to simulate biological responses without the use of live animals. This trend reflects a shift towards ethically conscious research practices and the rise of innovative technologies that enhance experimental efficiency.

## Regional Market Share Analysis

### North America : Leading Innovation and Research

North America is the largest market for animal models for testing, holding approximately 45% of the global share. The region benefits from advanced research facilities, significant investment in biotechnology, and a robust regulatory framework that supports animal testing. The increasing demand for innovative therapies and personalized medicine further drives market growth, with a focus on ethical standards and animal welfare regulations.

The United States is the primary contributor, with key players like Charles River Laboratories and Envigo leading the market. The competitive landscape is characterized by a mix of established firms and emerging companies, all striving to meet the growing demand for high-quality animal models. Canada also plays a significant role, contributing to the region's overall market strength, with a focus on regulatory compliance and ethical research practices.

### Europe : Regulatory Framework and Growth

Europe is the second-largest market for animal models, accounting for approximately 30% of the global share. The region's growth is driven by stringent regulations that ensure ethical treatment of animals in research, alongside increasing investments in pharmaceutical and biotechnology sectors. The European Union's commitment to reducing animal testing through alternative methods is also shaping market dynamics, pushing for innovation in testing methodologies.

Leading countries include Germany, the UK, and France, where significant research activities are concentrated. The competitive landscape features major players like Harlan Laboratories and Crown Bioscience, alongside numerous SMEs focusing on niche markets. The presence of regulatory bodies ensures compliance and fosters a culture of ethical research, enhancing the region's reputation in the global market.

### Asia-Pacific : Rapid Growth and Development

Asia-Pacific is witnessing rapid growth in the animal models for testing market, holding approximately 20% of the global share. The region's expansion is fueled by increasing investments in healthcare and biotechnology, coupled with a rising demand for innovative drug development. Countries like China and India are becoming significant players, supported by government initiatives aimed at enhancing research capabilities and regulatory frameworks.

China is the largest market in the region, with a growing number of research institutions and a focus on improving animal welfare standards. The competitive landscape is evolving, with both local and international companies, such as Wuxi AppTec, expanding their presence. The region's diverse market dynamics and regulatory environment are shaping the future of animal testing, making it a focal point for global research activities.

### Middle East and Africa : Untapped Potential and Growth

The Middle East and Africa region is gradually emerging in the animal models for testing market, currently holding about 5% of the global share. The growth is driven by increasing investments in healthcare infrastructure and a rising demand for research in pharmaceuticals and biotechnology. Governments are beginning to recognize the importance of animal testing in drug development, leading to a more favorable regulatory environment.

Countries like South Africa and the UAE are at the forefront, with growing research facilities and collaborations with international organizations. The competitive landscape is still developing, with opportunities for both local and global players to establish a foothold. As the region continues to invest in research and development, the animal testing market is expected to expand significantly in the coming years.

## Competitive Benchmarking

The Animal Model for Testing Market is characterized by a dynamic competitive landscape, driven by increasing demand for preclinical testing and the growing emphasis on personalized medicine. Key players such as Charles River Laboratories (US), Envigo (US), and Wuxi AppTec (CN) are strategically positioned to leverage their extensive portfolios and global reach. Charles River Laboratories (US) focuses on innovation through the development of advanced animal models that cater to specific therapeutic areas, while Envigo (US) emphasizes partnerships with biopharmaceutical companies to enhance its service offerings. Wuxi AppTec (CN) is expanding its capabilities in Asia, aiming to capture a larger share of the growing market in that region. Collectively, these strategies indicate a trend towards specialization and collaboration, shaping a competitive environment that prioritizes quality and tailored solutions.

In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness. The market appears moderately fragmented, with several players vying for dominance. However, the collective influence of major companies like Charles River Laboratories (US) and Envigo (US) suggests a trend towards consolidation, as these firms seek to enhance their competitive edge through strategic acquisitions and partnerships.

In August 2025, Charles River Laboratories (US) announced a strategic partnership with a leading biotechnology firm to develop novel animal models for oncology research. This collaboration is expected to enhance Charles River's portfolio, allowing it to offer more specialized models that meet the evolving needs of researchers. The strategic importance of this partnership lies in its potential to position Charles River as a leader in oncology preclinical testing, thereby attracting more clients in this lucrative segment.

In September 2025, Envigo (US) launched a new line of genetically modified mouse models designed for immunology studies. This initiative reflects Envigo's commitment to innovation and its focus on providing cutting-edge solutions to its clients. By expanding its product offerings, Envigo aims to strengthen its market position and cater to the growing demand for specialized animal models in immunological research.

In July 2025, Wuxi AppTec (CN) expanded its facilities in Shanghai to enhance its animal testing capabilities. This expansion is indicative of Wuxi's strategy to capitalize on the increasing demand for preclinical services in Asia. By bolstering its infrastructure, Wuxi AppTec is likely to improve its service delivery and attract more clients, thereby reinforcing its competitive position in the region.

As of October 2025, current trends in the Animal Model for Testing Market include a strong focus on digitalization, sustainability, and the integration of artificial intelligence in research processes. Strategic alliances are becoming increasingly important, as companies recognize the value of collaboration in driving innovation and improving service offerings. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on technological advancements, innovative solutions, and reliable supply chains. This transition may redefine the competitive landscape, emphasizing the need for companies to adapt and innovate continuously.

## Report Scope

| MARKET SIZE 2024 | 2.09(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 2.301(USD Billion) |
| MARKET SIZE 2035 | 6.018(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.09% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Market analysis in progress |
| Segments Covered | Market segmentation analysis in progress |
| Key Market Opportunities | Advancements in genetic engineering enhance precision in the Animal Model for Testing Market. |
| Key Market Dynamics | Rising demand for ethical testing drives innovation and regulatory scrutiny in the Animal Model for Testing Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Animal Model for Testing Market?**
A: The market valuation was 2.09 USD Billion in 2024.

**Q: What is the projected market size for the Animal Model for Testing Market by 2035?**
A: The projected valuation for 2035 is 6.018 USD Billion.

**Q: What is the expected CAGR for the Animal Model for Testing Market during the forecast period?**
A: The expected CAGR for the market from 2025 to 2035 is 10.09%.

**Q: Which companies are considered key players in the Animal Model for Testing Market?**
A: Key players include Charles River Laboratories, Envigo, Taconic Biosciences, and others.

**Q: What are the primary segments of the Animal Model for Testing Market?**
A: The market segments include Animal Type, Application, Technology, End-User, and Modality.

**Q: How do rodent models perform in terms of market valuation?**
A: Rodent models, specifically mice and rats, had a valuation of 1.045 USD Billion in 2024 and are projected to reach 2.845 USD Billion.

**Q: What is the market valuation for non-rodent animal models?**
A: Non-rodent models, including rabbits, dogs, and primates, were valued at 1.045 USD Billion in 2024 and are expected to grow to 3.173 USD Billion.

**Q: Which application segment shows the highest growth potential in the market?**
A: The Drug Discovery and Development segment had a valuation of 0.83 USD Billion in 2024 and is projected to reach 2.4 USD Billion.

**Q: What is the valuation trend for genetically modified animal models?**
A: Genetically modified animal models were valued at 0.75 USD Billion in 2024 and are expected to grow to 2.25 USD Billion.

**Q: How do academic research institutions contribute to the market?**
A: Academic research institutions had a market valuation of 0.21 USD Billion in 2024 and are projected to reach 0.6 USD Billion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/animal-model-for-testing-market-29720*